Topical Rapamycin for Fibrofolliculomas
The purpose of the study is to determine whether topical application of rapamycin can lead to reduction in size and/or number of fibrofolliculomas in BHD patients and may prevent the growth of new ones. Secondary we evaluate rapamycin safety, formula acceptance and patient satisfaction.
Birt-Hogg-Dub√© Syndrome
DRUG: Rapamycin|DRUG: placebo
Significant regression of lesions (reduction of fibrofolliculoma size and count) in the treated area., 3 and 6 months
Side effects, 3 and 6 months
The purpose of the study is to determine whether topical application of rapamycin can lead to reduction in size and/or number of fibrofolliculomas in BHD patients and may prevent the growth of new ones. Secondary we evaluate rapamycin safety, formula acceptance and patient satisfaction.